Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11752
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain
Identifiers
ISSN: 1932-6203
WOS ID: 000532710400025
Scopus EID: 2-s2.0-85074927760
PMID: 31714950
Embase PUI: L2003761215
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Manuel Sousa, Jose; Vergara, Mercedes; Pulido, Federico; Sanchez Antolin, Gloria; Hijona, Lander; Carnicer, Fernando; Rincon, Diego; Salmeron, Javier; Mateos-Munoz, Beatriz; Jou, Antoni; Polo-Lorduy, Benjamin; Rubin, Angel; Escarda, Ana; Aguilar, Patricia; Aldamiz-Echevarria, Teresa; Garcia-Buey, Luisa; Carrion, Jose A.; Hernandez-Guerra, Manuel; Chimeno-Hernandez, Sonia; Espinosa, Nuria; Morillas, Rosa Ma; Andrade, Raul J.; Delgado, Manuel; Gallego, Adolfo; Magaz, Marta; Maria Moreno-Planas, Jose; Estebanez, Angel; Rico, Mikel; Menendez, Fernando; Sampedro, Blanca; Morano, Luis; Izquierdo, Sonia; Manuel Zozaya, Jose; Rodriguez, Manuel; Moran-Sanchez, Senador; Lorente, Sara; Martin-Granizo, Ignacio; Angel Von-Wichmann, Miguel; Delgado, Marcial; Manzanares, AmandaPublication date
2019-11-12Document type
research articleCitation
Manuel Sousa J, Vergara M, Pulido F, Sanchez AG, Hijona L, Carnicer F, et al. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One. 2019 Nov 12;14(11):e0225061.Abstract
Aim We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r +/- DSV +/- RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain. Material and methods Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r +/- DSV +/- RBV at 61 Spanish sites within the initial implementation year of the first government-driven National HCV plan. Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a non-inferiority margin of 5% and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or patients and adverse events (AEs) were also recorded. Results Overall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in each participating region in Spain. From the total population, 96.6% (95% CI, 95.8-97.3%) achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference between monoinfected and coinfected patients of -2.2% (90% CI, -4.5% - 0.2%). Only genotype 4 was associated with non-response to OBV/PTV/r +/- DSV +/- RBV treatment (p < 0.001) in the multivariate analysis. Overall, 286 patients (11.9%) presented AEs potentially related to OBV/PTV/r +/- DSV, whereas 347 (29.0%) presented AEs potentially related to ribavirin and 61 (5.1%) interrupted ribavirin. Conclusions Our results confirm that OBV/PTV/r +/- DSV +/- RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.
Publisher version
https://dx.doi.org/10.1371/journal.pone.0225061MeSH
CarbamatesMacrocyclic Compounds
Anilides
Spain
Antiviral Agents
Follow-Up Studies
Humans
Drug Therapy, Combination
Middle Aged
Sulfonamides
Sustained Virologic Response
HIV Infections
Male
Multivariate Analysis
Female
Treatment Outcome
HIV-1
Hepatitis C, Chronic
Ribavirin
Logistic Models
Uracil
DeCS
VIH-1Respuesta Virológica Sostenida
Resultado del Tratamiento
Hepatitis C Crónica
Modelos Logísticos
Uracilo
Femenino
Infecciones por VIH
Análisis Multivariante
Compuestos Macrocíclicos
Sulfonamidas
Masculino
Estudios de Seguimiento
Quimioterapia Combinada
Humanos
Persona de Mediana Edad
Antivirales
Carbamatos
Ribavirina
Anilidas
España
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaRelated items
Showing items related by title, author, creator and subject.
-
Role of age and comorbidities in mortality of patients with infective endocarditis
Arminanzas, Carlos; Farinas-Alvarez, Concepcion; Zarauza, Jesus; Munoz, Patricia; Gonzalez Ramallo, Victor; [et al.] (research article. 2019-06) -
Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort
Pericas, Juan M.; Llopis, Jaume; Gonzalez-Ramallo, Victor; Goenaga, Miguel A.; Munoz, Patricia; [et al.] (research article. 2019-11-15)